**Table 1.** The ideal responses to the tyrosine kinase inhibitor (TKI) treatment detectable during the long-term monitoring of chronic myeloid leukemia (CML)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Ideal response at the 3rd month of TKI** | **Ideal response at the 6th month of TKI** | **Ideal response at the 12th month of TKI** | **Ideal response after one year of TKI and thereafter** |
| **Hematological monitoring** | CHR | CHR | CHR | CHR |
| **Cytogenetic monitoring** | MCyR | CCyR | CCyR | CCyR |
| **Molecular monitoring** | BCR-ABL/ABL below 10% | BCR-ABL/ABL below 10% | MMR | better than MMR; MR4, MR4.5, MR5 |

CHR; complete hematological response

MCyR; major cytogenetic response

CCyR; complete cytogenetic response

MMR; major molecular response